Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImExHSASX:IME -3.13%48 Days Sales Outstanding is 86.03 as of Dec. 2025, which is 29% below its 10-year median of 121.95. GuruFocus rates ASX:IME with a GF Score™ of 48/100 and a GF Value™ of A$0.51 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, ImExHS ranks worse than 61.39% on this metric.
ImExHS's average Accounts Receivable for the
six
months ended in Dec. 2025 was A$7.22 Mil. ImExHS's Revenue for the
six
months ended in Dec. 2025 was A$15.32 Mil.
Hence, ImExHS's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 86.03.
The historical rank and industry rank for ImExHS's Days Sales Outstanding or its related term are showing as below:
ASX:IME'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 69.95 Med: 121.95 Max: 360.44
Current: 81.25
During the past 13 years, ImExHS's highest Days Sales Outstanding was 360.44. The lowest was 69.95. And the median was 121.95.
ASX:IME's Days Sales Outstanding is ranked worse than 61.39% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.76
vs ASX:IME: 81.25
ImExHS's Days Sales Outstanding
increased
from Dec. 2024 (78.40) to Dec. 2025 (86.03).
ImExHS (ASX:IME) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
ImExHS Days Sales Outstanding Related Terms
ImExHS Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for ImExHS's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IME vs TMO, DHR, IDXX: Days Sales Outstanding Comparison
For the Diagnostics & Research subindustry, ImExHS's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImExHS Days Sales Outstanding vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ImExHS's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where ImExHS's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ImExHS (ASX:IME) has a Days Sales Outstanding of 86.03 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on ImExHS and its competitors. This is 29% below median its historical median of 121.95. Over the past decade, ImExHS's Days Sales Outstanding has ranged from 69.95 to 360.44. According to the industry distribution chart, ImExHS ranks #124 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 61.4%.
Is ImExHS's Days Sales Outstanding too high?
ImExHS's current Days Sales Outstanding of 86.03 is 29% below median its 10-year median of 121.95. Over the past 10 years, this metric has ranged from a low of 69.95 to a high of 360.44. The Medical Diagnostics & Research industry median Days Sales Outstanding is 67.76. ImExHS's value of 86.03 is 27% above this industry median. Based on the distribution chart, ImExHS ranks #124 out of 202 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, ImExHS has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ImExHS's Days Sales Outstanding compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, ImExHS ranks #124 out of 202 companies for Days Sales Outstanding. This places ImExHS in the lower half of its industry. The industry median Days Sales Outstanding is 67.76. ImExHS's value of 86.03 is 27% above this benchmark. Historically, ImExHS's own Days Sales Outstanding has ranged from 69.95 to 360.44 over the past decade. While the company's 10-year median is 121.95 vs. the industry median of 67.76, ImExHS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Diagnostics & Research company?
The median Days Sales Outstanding among Medical Diagnostics & Research companies is 67.76, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ImExHS's current Days Sales Outstanding of 86.03 is 27% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on ImExHS and its competitors. For the Medical Diagnostics & Research industry, the median Days Sales Outstanding is 67.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ImExHS's current Days Sales Outstanding is 86.03, which is 29% below median its own 10-year median of 121.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImExHS stock overvalued right now?
Based on GuruFocus' analysis, ImExHS (ASX:IME) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.51, compared to a current price of A$0.31 — trading 39.2% below its estimated fair value. The current Days Sales Outstanding is 86.03, which is 29% below median its 10-year median of 121.95 and 27% above the Medical Diagnostics & Research industry median of 67.76. ImExHS's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For ImExHS (ASX:IME), the current Days Sales Outstanding is 86.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ImExHS (ASX:IME) Overvalued in 2026?
Based on GuruFocus' analysis, ImExHS stock appears to be undervalued.
The current stock price of A$0.31 is trading 39.2% below its estimated GF Value™ of A$0.51.
GuruFocus considers ImExHS to be Possible Value Trap.
Key valuation signals for ASX:IME:
Days Sales Outstanding: 86.03 (29% below median its 10-year median of 121.95)
GF Value™: A$0.51 vs. price of A$0.31 (39.2% below fair value)
Industry Position: 27% above the Medical Diagnostics & Research median (#124 of 202)
No single metric tells the full story. See the ASX:IME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ImExHS Ltd is a healthcare technology company engaged in the provision of medical imaging software and radiology services. The company develops and delivers enterprise imaging solutions, including radiology information systems and picture archiving and communication systems, as well as provides diagnostic imaging and teleradiology services to healthcare institutions. The company operates through two reportable segments: Software, which focuses on the development and sale of imaging systems and platforms, and Radiology Services, which provides diagnostic and teleradiology services to hospitals and medical facilities. It generates the majority of its revenue from the Radiology segment.
48GF Score
Get the complete analysis for ASX:IME
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IME has been successfully added to your 
